The FDA approved Enspryng (satralizumab) on Oct. 16 for adults with thyroid eye disease (TED). 1 Roche describes the ...
After months of prodding, the European Medicines Agency (EMA) and member states of the European Union have begun taking ...
President Trump’s Most-Favored Nation (MFN) initiative continues to impact the industry. Most recently, the deadline passed ...
Pharmaceutical Executive spoke with Marc Wagner, an FDA and life sciences attorney at Fox Rothschild, about the manufacturing ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization in the European Union for Eli Lilly’s Foundayo ...
AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization. There is a conversation happening in boardrooms and brand planning cycles across the pharmaceutical industry ...
The advantage comes from bringing all three into a disciplined decision process. Executives must recognize when experience ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results